Lipocine exhibits a precarious liquidity profile, with quarterly operating losses reaching $3.8 million in 2026Q1 against a limited cash balance of only $5.2 million.
Lipocine Inc. (LPCN) cash flow statement — 15-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|
| Cash from Operations | -11.19M | -9.76M | -1.22M | -11.87M | -11.97M | -4.41M | -15.3M | -11.67M | -12.08M | -16.7M | -18.28M | -15.36M | -17.3M | -8.59M | -62.87K | -7.29K |
| Operating CF Margin % | - | -493.79% | -10.91% | 416.23% | -2393.76% | -27.33% | - | -7070.86% | -2821.95% | - | - | - | - | - | -0.82% | - |
| Operating CF Growth % | -352.11% | -699.25% | 89.71% | 0.86% | -171.32% | 71.17% | -31.17% | 3.42% | 27.68% | 8.64% | -19.05% | 11.26% | -101.48% | -13561.53% | -761.77% | - |
| Net Income | -11.85M | -9.63M | 8.35K | -16.35M | -10.76M | -634.4K | -20.96M | -13.01M | -11.66M | -20.98M | -18.97M | -18.21M | -20.37M | -10.59M | -76.65K | -5.16K |
| Depreciation & Amortization | 58.57K | 60.78K | 41.11K | 28.66K | 9.45K | 380 | 3.55K | 15.44K | 18.59K | 28.37K | 31.96K | 26.72K | 14.62K | 21.77K | 42.57K | 0 |
| Stock-Based Compensation | 229.83K | 242.5K | 408.55K | 654.44K | 636.14K | 603.95K | 1.37M | 1.04M | 1.46M | 2.72M | 2.37M | 1.15M | 1.89M | 979.15K | 127.49K | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 159.69K | 0 | 0 | -160.87K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -261.16K | -192.94K | -715.03K | 1.8M | -932.15K | 53.75K | 2.76M | -179.5K | 259.87K | -99.89K | 224.48K | 181.39K | -449.56K | 917.26K | -7.11M | -5.16K |
| Working Capital Changes | 633.38K | -243.56K | -964.21K | 2.01M | -923.63K | -4.59M | 1.52M | 469.35K | -1.99M | 1.64M | -1.94M | 1.49M | 1.16M | 83.47K | 13.79K | -2.13K |
| Change in Receivables | 975.96K | 106.26K | -68.19K | 738.11K | 384.9K | -246.86K | 16.13K | 21.99K | 3.3M | -3.3M | 105.59K | -144.54K | 0 | 0 | 313.75K | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | -384.9K | 246.86K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 237.53K | 700.13K | -1.12M | 795.59K | -688.95K | -307.88K | 414.98K | 510.96K | 73.21K | 352.15K | -261.15K | 200.79K | -449.56K | 668.81K | 4.29K | 0 |
| Cash from Investing | -6.15M | 5.89M | 2.45M | 13.08M | 14.29M | -43.78M | 3.89M | 3M | 11.29M | 3.13M | 3.23M | -25.02M | -38.36K | -1.21K | -12.32K | 0 |
| Capital Expenditures | 0 | 0 | -90.09K | -13.17K | -133.83K | -7.59K | 0 | 0 | 0 | 0 | -59.65K | -28.69K | -59.61K | -1.21K | -12.32K | 0 |
| CapEx % of Revenue | 0% | 0% | 0.8% | -0.46% | 26.77% | 0.05% | - | - | - | - | - | - | - | - | 0.16% | - |
| Acquisitions | 0 | 0 | 0 | 0 | -14.29M | 43.78B | 0 | 0 | 0 | 0 | 0 | 25.02M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 14.29M | -43.78B | 0 | 0 | 7K | 3.13M | -7K | -25.02M | 21.25K | -1.21K | 0 | 0 |
| Cash from Financing | 16.27M | 2.87M | 209.34K | 404.57K | -2.13M | 26.92M | 20.9M | 10.32M | 10.65M | 11.23M | 605.87K | 32.72M | -255.12K | 48.48M | 40.5K | 30.24K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | -2.32M | -3.33M | -1.43M | -3.33M | 10M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 16.27M | 2.87M | 209.34K | 404.57K | 211.42K | 30.25M | 14.66M | 13.6M | 652.33K | 10.64M | 0 | 32.44M | 0 | 48.52M | 40.5K | 30K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -21.7K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -53.1K | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | -21.7K | 11.69K | 7.67M | 56.35K | 0 | 581.14K | 605.87K | 276.99K | -255.12K | -42.52K | 0 | 238 |
| Net Change in Cash | -1.06M | -1M | 1.43M | 1.62M | 197.94K | -21.27M | 9.49M | 1.65M | 9.87M | -2.35M | -14.45M | -7.66M | -17.6M | 39.89M | -22.37K | 22.94K |
| Free Cash Flow | -11.19M | -9.76M | -1.31M | -11.88M | -12.1M | -4.42M | -15.3M | -11.67M | -12.08M | -16.7M | -18.34M | -15.38M | -17.36M | -8.59M | -75.18K | -7.29K |
| FCF Margin % | -713.03% | -493.79% | -11.71% | 416.69% | -2420.53% | -27.38% | - | -7070.86% | -2821.95% | - | - | - | - | - | -0.98% | - |
| FCF Growth % | -120.44% | -644.34% | 88.96% | 1.85% | -173.88% | 71.12% | -31.17% | 3.42% | 27.68% | 8.94% | -19.22% | 11.4% | -102.15% | -11325.16% | -930.6% | - |
| FCF per Share | -1.36 | -1.71 | -0.24 | -2.25 | -2.30 | -0.86 | -4.67 | -7.66 | -9.62 | -14.16 | -17.08 | -15.88 | -23.12 | -19.83 | -0.29 | -4.14 |
| FCF Conversion (FCF/Net Income) | 0.94x | 1.01x | -146.22x | 0.73x | 1.11x | 6.95x | 0.73x | 0.90x | 1.04x | 0.80x | 0.96x | 0.84x | 0.85x | 0.81x | -0.02x | 1.41x |
| Interest Paid | 0 | 0 | 0 | 0 | 21.26K | 149.54K | 276.02K | 545.54K | 533.54K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 681 | 225 | 200 | 200 | 200 | 200 | 700 | 700 | 752 | 200 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying LPCN stock.
Lipocine Inc. (LPCN) generated $-9.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Lipocine Inc. (LPCN) reported negative free cash flow of $9.8M in 2025, indicating capital requirements exceeded cash from operations.
Lipocine Inc. (LPCN) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Imminent liquidity and dilution
Metrics are mathematically derived from official filings.
Earnings Quality Obscured by Milestones
According to the provided cash flow data, Lipocine's operating cash flow consistently tracks net losses, with an OCF/NI ratio that fluctuates wildly, suggesting that reported earnings are heavily distorted by the timing of non-recurring milestone payments rather than reflecting underlying operational cash generation or sustainable business quality.
The disconnect between net income and operating cash flow highlights the absence of a recurring revenue engine. Investors should note that the company's inability to generate positive cash flow from operations, even in quarters with milestone recognition, indicates that the core business model remains fundamentally cash-consumptive.
Persistent Free Cash Flow Deficits
As reported in financial statements, Lipocine's free cash flow trajectory remains deeply negative, with quarterly burn rates frequently exceeding $2 million, which underscores the company's reliance on external capital to fund its clinical pipeline in the absence of meaningful, self-sustaining product-driven cash inflows.
The consistent negative FCF margins suggest that the company is effectively subsidizing its R&D efforts through equity dilution. This trend warrants close monitoring, as the lack of a clear path to positive FCF suggests that the current operational structure is not yet viable without continuous capital market access.
Working Capital Volatility Signals Instability
Based on the company's reported figures, working capital changes have been highly erratic, swinging from a $1.4 million inflow in 2026Q1 to a $1.0 million outflow in 2024Q1, which reflects the unpredictable nature of milestone-based accounting and the lack of a stable, repeatable commercial operating cycle.
These fluctuations in working capital suggest that the company's cash position is highly sensitive to the timing of contractual payments. Such volatility makes it difficult for analysts to forecast liquidity needs, as the cash balance is subject to the timing of partner payments rather than operational efficiency.
Hidden Costs of Clinical Development
Analysis of the cash flow statement reveals that Lipocine's R&D-heavy cost structure is not fully captured by headline expenses, as the company's reliance on specialized manufacturing and clinical trial management creates significant cash outflows that are not offset by the current, limited commercial royalty streams.
The cash flow statement obscures the true cost of maintaining the Lip'ral platform, as capitalized costs and R&D burn are not balanced by any meaningful product-related cash inflows. Investors should be wary that the current cash burn may accelerate if clinical trial enrollment for the LPCN 1148 program intensifies.